Modifying the major model of a modern major mouse model

August 23, 2018 by Garth Sundem, CU Anschutz Medical Campus
Antonio Jimeno, MD, PhD and colleagues show that two kinds of stem cells are better than one when transplanting human immune system into mice. Credit: University of Colorado Cancer Center

If a new anti-cancer drug shows promise in a Petri dish, often the next step is to test the drug's effect in mice. This system tends to work well with drugs that directly target cancer, but breaks down with immunotherapies. That's because tumors from human cancer samples can only grow in mice with suppressed immune systems. Immunotherapies activate the immune system against cancer. And in a mouse model in which the immune system has been suppressed, there is no immune system to activate against cancer.

One answer to this challenge has been the effort to create "humanized" mice. Basically, a human immune system is transplanted into mice along with the human tumor. A truly humanized model would allow researchers to test the ability of immunotherapies to direct a human immune system against a human ...in a mouse.

Unfortunately, mice have tended to resist humanization.

The procedure is a bit like a transplant used to treat leukemia. Commonly, chemotherapy or radiation is used to knock out a patient's blood system, after which a new (non-cancerous) blood system is grown from bone marrow from a healthy donor. Only, when researchers have used a similar approach to delete and replace the mouse immune system, the result has been lackluster—only small numbers of populate the mouse bone marrow, few immune circulate near the tumor, and fewer immune cells penetrate the tumor.

A study published today in the journal Molecular Carcinogenesis describes significant progress toward a more complete humanized mouse model. By using not only human hematopoietic stem and progenitor cells (HSPCs), but also (MSCs) to seed a human immune system in mice, researchers were able to grow an immune system that much more faithfully represented the conditions of a human immune system, leading to more realistic immunotherapy test results in these models.

"We need both kinds of cells. HSPCs give rise to blood cells like T cells and B cells; MSCs seem to assist the bone marrow to generate more of those blood cells and also other cell types such as macrophages and fibroblasts. We've known from transplantation in humans that these sides of the immune system cooperate. Now we see something similar when engrafting human immune systems in mice," says Antonio Jimeno, MD, Ph.D., director of the Head and Neck Cancer Clinical Research Program at the University of Colorado Cancer Center, a member of the Gates Center for Regenerative Medicine, and the Daniel and Janet Mordecai Endowed Chair for Cancer Stem Cell Research at the CU School of Medicine.

The stem cells used in the study were purified from donated cord blood and then grown to sufficient quantity in the lab before being infused into mice.

"There's not a perfect model and all models have limitations, but it's important to try to move the field forward. Sometimes you get a touchdown and sometimes you just go one yard at a time. This study describes many of these one-yard runs as we've been incrementally learning over the course of years," says J. Jason Morton, Ph.D., assistant research professor in the CU School of Medicine Division of Medical Oncology, and the paper's first author.

The use of both HSPCs and MSCs produced mice with almost twice the percentage of human immune cells in their bone marrow, compared to mice engrafted with HSPCs alone. Increased bone marrow immune cells in turn produced 9- to 38-fold higher levels of mature human immune cells circulating in the blood system. And were not only increased in circulation, but were enriched inside of tumors. Specifically, T cells, B cells and macrophages in the tumors of mice that had been developed in this way were 2-8 times higher than in models that were developed with HSPCs alone.

"At the end of the day, what you want to generate with these models is a system that allows you to ask questions," says Xiao-Jing Wang, MD, Ph.D., CU Cancer Center investigator and the John Gates Endowed Chair of Cancer Stem Cell Biology at the Gates Center for Regenerative Medicine.

Interestingly, the ongoing work has allowed the group to compare interaction of the immune system with the tumor in three settings, namely the mouse models available before 2014, the mouse models available today, and the patients who had originally donated tumor samples. The modern mouse much more meticulously matched the original patient tumor, and immunotherapy treatment led to tumor regression in well-humanized mice (but not in poorly humanized implanted with the same patient tumor).

"We have come to realize that when we use this dual engraftment, the tumors that grow on the mouse represent more faithfully what we know the original patient tumors looked like," Jimeno says.

The group is now working to take their humanized mouse model a step further, using sample and from the same patient. If successful, the model could someday allow doctors to preview how an immunotherapy might work with a specific patient, guiding treatment decisions.

Explore further: 'Humanized' mice will lead to better testing of cancer immunotherapies

More information: J. Jason Morton et al, Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer, Molecular Carcinogenesis (2018). DOI: 10.1002/mc.22887

Related Stories

'Humanized' mice will lead to better testing of cancer immunotherapies

April 23, 2015
Human tumors grown in mouse models have long been used to test promising anti-cancer therapies. However, when a human tumor is transplanted into a mouse, the mouse immune system must be knocked down so that it doesn't attack ...

Some blood stem cells are better than others

May 30, 2018
In your body, blood stem cells produce approximately 10 billion new white blood cells, which are also known as immune cells, each and every day. Even more remarkably, if some of these blood stem cells fail to do their part, ...

New model paves way for immune therapies against colorectal cancer

April 3, 2017
About 95 percent of colorectal cancers are considered "microsatellite stable" and very few of these cancers respond to immunotherapy, meaning that the vast majority of metastatic colorectal cancer patients are unable to benefit ...

Mosquito spit may affect your immune system for days

May 17, 2018
Mosquito saliva alone—even in the absence of any pathogens—contains hundreds of proteins. Now, researchers reporting in PLOS Neglected Tropical Diseases have discovered that the interaction of these proteins with the ...

Study reveals secrets of "hot" and "cold" pancreatic cancer tumors

June 28, 2018
So-called "hot" tumors filled with T cells are often considered to be more sensitive to immunotherapy compared to "cold" tumors with fewer T cells, but a clear demonstration of why has eluded cancer biologists—until now. ...

Researchers discover new approach to stimulate an immune response against tumor cells

January 30, 2018
New drugs that activate the immune system to target cancer cells have improved the lives of many patients with cancer. However, immunotherapies are not effective in all patients, and the success of these therapies depends ...

Recommended for you

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.